Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Banyu/Merck’s Cervical Cancer Vaccine Gardasil Receives WHO Prequalification

This article was originally published in PharmAsia News

Executive Summary

Merck Japanese subsidiary Banyu Pharmaceutical June 4 announced that human papillomavirus quadrivalent vaccine Gardasil obtained World Health Organization prequalification, which recognizes the efficacy and safety of the vaccine and enables United Nation agencies to purchase the vaccine for immunization purposes. Gardasil is approved in 111 countries and has not yet been approved in Japan. The prequalification could help the drug obtain faster Japanese approval. (Click here for more - Japanese language
UsernamePublicRestriction

Register

SC072095

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel